loading

Loading...

Archive by Tag: clinical investigators

Clinical Trials—The New Way Forward

Industry Insights from Paul Meade, M. Sc, MPH A recent article in the Wall Street Journal announced that Pfizer is conducting a clinical trial in which patients are able to use their computers and smartphones to enter information about the[...]

Clinical Trial Ethics

Industry Insights from Paul Meade, M. Sc, MPH According to an article published in the Archives of Internal Medicine, Dr Joseph Ross claimed a study conducted by Parke-Davis, before it was acquired by Pfizer, using gabapentin (Neurontin), as the drug[...]

Successful Product Launches with the Right Thought Leaders

Industry Insights from Paul Meade, M. Sc, MPH When a biopharmaceutical company introduces a new medicine to the market, it comes after years of research, years of clinical development, and some times even years of regulatory review. With the patent[...]

Thought Leader Select delivers KOL identification research to five leading pharma companies in the U.S. and Canada

April 15, 2010 (CHAPEL HILL, NC)—Thought Leader Select, a North Carolina-based firm dedicated to delivering solutions for key opinion leader (KOL) management for the biopharmaceutical industry, has announced the delivery of KOL identification projects for five leading North American pharmaceutical[...]

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Five

Over the past several weeks, we’ve talked about how collaborations among key opinion leaders, clinical investigators and pharmaceutical and biotechnology companies benefit the companies, the KOLs or clinical investigators, and patients. The foundation of these mutually-beneficial collaborations is the objective,[...]

The Trifecta of Mutually-Beneficial Relationships: KOLs, Pharma, and Patients—Part Four

Pharmaceutical & Biotechnology Companies Provide Early Knowledge-building Opportunities for KOLs and Clinical Investigators Understanding the value that key opinion leaders provide pharmaceutical and biotechnology companies is clear, but how do companies benefit thought leaders and clinical investigators? By definition, KOLs[...]

Industry Contraction Spurs New Partnership Opportunities

According to a February 2010 article in Outsourcing-Pharma.com, pharmaceutical companies will continue to outsource more of their business to single-service providers. To capture more business, CROs will merge or focus on niche opportunities. Thought Leader Select, a research firm providing[...]